PGNY · CIK 0001551306
What Progyny, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for PGNY. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- Pharmaceutical-drug tariffs could raise costs in its Progyny Rx pharmacy benefit (fertility medications) and affect its pharmacy program partnerslow
Progyny's Progyny Rx integrated pharmacy benefit — about $458 million, or ~35%, of 2025 revenue — dispenses fertility medications, some of which (or whose components) are imported, exposing it to drug-tariff policy. It discloses that the U.S. and other governments may impose tariffs on certain pharmaceutical drugs and their components affecting pharmaceutical imports, and that Progyny, its customers, suppliers and its pharmacy program partners could then become subject to additional tariffs and adverse business impacts. If it cannot mitigate, tariffs and broader trade barriers could raise the cost of the fertility medications underlying its pharmacy benefit. A pharma-specific trade-policy exposure (its employer-client base is otherwise diffuse — no client exceeded 10% of revenue in 2025).
“The U.S. government and other governments may impose tariffs on certain pharmaceutical drugs and their components that may impact pharmaceutical imports into the United States, and we, our customers, suppliers, and our pharmacy program partners may then become subject to additional tariffs and adverse business impacts.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch